Streetwise Biotechnology / Pharmaceuticals Articles


Several Milestones on Horizon for 'Top Pick' Immunotherapy Firm

Research Report
  ()
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status. read more >

Test for Personalized Approach to Hodgkin's Lymphoma Treatment Entering Final Stages Before Commercialization

  ()
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment. read more >

Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's'

Research Report
  ()
André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug. read more >

Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018

Contributed Opinion
  ()
As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. read more >

2018 Biotech Watchlist: 'No One Space Is Going to Dominate'

  ()
Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors. read more >

Portfolio Manager's Biotech Watchlist Picks for 2018

  ()
StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist. read more >

2017: A Year of Triple Digit Stock Performance

  ()
As stock indexes in the U.S. hit record highs in 2017, we take a look at some of the best performers profiled by Streetwise Reports in the last year, some of which have seen triple digit increases. read more >

Biotech's Shares 'Undervalued' and Positioned for 'Long-Term Upside Potential'

Research Report
  ()
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease. read more >

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect. read more >

Updates from ASH Reinforce Analyst's Big Price Target Potential

Research Report
  ()
Andrew Fein, an analyst with H.C. Wainwright & Co., discussed the implications of this biopharmaceutical's recently announced data, which support his "bullish" outlook for the firm's candidate in chronic graft versus host disease. read more >

Biotech Receives 'Major Endorsement from World-Leading Pharma Company'

Research Report
  ()
David Kideckel, an analyst with Beacon Securities Ltd., relayed news from this firm's recent annual meeting, including a private placement with a large pharma and an update on the Phase 3 trial of its lead therapy. read more >

'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform

Research Report
  ()
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. read more >

Cannabis Biotech Stock Starting to Advance Again

Contributed Opinion
  ()
A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock. read more >

'The Market Gets it Wrong, Again'; Analyst Raises Target Price on Biotech

Research Report
  ()
Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got. read more >

Biotech Delivers 'Great' Phase 2 Data in NASH

Contributed Opinion
  ()
John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market. read more >

A New Breed of Regenerative Therapy Companies Taking Hold

Contributed Opinion
  ()
A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research. read more >

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results

  ()
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts. read more >

Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada'

Research Report
  ()
David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm. read more >

Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China

Research Report
  ()
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies. read more >

Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate

Contributed Opinion
  ()
Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. read more >

Potential Alzheimer's Therapies Focus on Early Intervention

Research Report
  ()
After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.C. Wainwright & Co., provided an industry update. read more >

Analyst's 'Top Pick' Advances Vaccine Candidates

Research Report
  ()
Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. read more >

Stock Price Jump Reflects Biotech's Active October

Research Report
  ()
This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment. read more >

Maxim's Target Price on Biotech Makes It More Than a Tenbagger

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets. read more >

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate

Research Report
  ()
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer. read more >
Showing Results: 1 to 25 of 169 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

More Experts